Erratum to "Open-Label, Randomized, Controlled, Crossover Trial on the Effect of Dapagliflozin in Patients With ADPKD Receiving Tolvaptan" [<i>Kidney International Reports</i> Volume 10, Issue 4, April 2025, Pages 1063-1075].
「關於『Dapagliflozin 對接受 Tolvaptan 治療之 ADPKD 患者影響的開放標籤、隨機、對照、交叉試驗』一文的更正啟事」
Kidney Int Rep 2025-07-18
Urinary Clusterin is a Biomarker of Renal Epithelial Senescence and Predicts Human Kidney Disease Progression.
尿液 Clusterin 為腎臟上皮細胞衰老的生物標誌，並可預測人類腎臟疾病進展
Kidney Int Rep 2025-07-18
Erratum to "Using the International IgA Nephropathy Prediction Tool to Enrich Clinical Trial Cohorts" [<i>Kidney International Reports</i> Volume 10, Issue 4, April 2025, Pages 1283-1287].
「更正啟事：使用 International IgA Nephropathy Prediction Tool 以優化臨床試驗受試者選擇」
Kidney Int Rep 2025-07-18
Corrigendum to "Lower Parathyroid Hormone Levels are Associated With Reduced Fracture Risk in Japanese Patients on Hemodialysis" [<i>Kidney International Reports</i> Volume 9, Issue 10, October 2024, Pages 2956-2969].
「更正啟事：『日本血液透析患者中較低的副甲狀腺素（Parathyroid Hormone）水準與骨折風險降低相關』[Kidney International Reports 第9卷第10期，2024年10月，頁2956-2969]」
Kidney Int Rep 2025-07-18
Point-of-Care Testing and Integrated Digital Health Technology for CKD Screening in High-Risk Populations of India.
印度高風險族群慢性腎臟病（CKD）篩檢之即時檢驗與整合型數位健康科技
Kidney Int Rep 2025-07-18
**重點整理：**
這則公告是針對先前已在《Kidney International Reports》期刊發表的多篇文章進行更正，這些文章都已經用各自的DOI編號標示出來。
相關文章PubMedDOI推理
Validation of 2 Prognostic Models to Predict Renal Allograft Outcome After IgA Nephropathy Recurrence.
兩種預後模型於 IgA Nephropathy 復發後預測腎臟移植結果之驗證
Kidney Int Rep 2025-07-18